Pharmacologic treatments for covid-19 patients

Methods

Protocol

Protocol amendment:

As of March 1, 2022, the COVID-NMA revised its protocol to include only studies evaluating immunomodulators and antiviral therapies. Comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.

For treatments that are neither immunomodulators nor antivirals, we provide the updated results up to Feb 28, 2022 including all identified reports through our search strategy up tp this date.

meta-COVID

Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:

go to metacovid

Treatment comparisons

Create and download your forest plots with the most up-to-date data here Forest plots

Search by treatment name :

Display new or updated analyses

Display all results

Your research: Nirmatrelvir

Access the forest plots for the 1 treatment comparisons .

    Anti-virals (1 comparisons)

Search studies

Search by Author Registration number

General characteristics of primary studies

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04960202
EPIC-HR
Hammond J, N Engl J Med, 2022
Full text
Commentary
Private

Nirmatrelvir/r

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated by 343 centers in 21 countries N=2246
Some concerns
Details

Full description